Long-term outcomes of living donor liver transplantation in patients with a prior history of nonhepatic malignancy
| Autor: | Hidekazu Yamamoto, Keita Shimata, Yasuhiko Sugawara, Taizo Hibi, Sho Ibuki, Yuzuru Sambommatsu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Larynx
Male endocrine system medicine.medical_specialty Health (social science) medicine.medical_treatment Liver transplantation Malignancy Gastroenterology Risk Assessment General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Internal medicine Neoplasms medicine Living Donors Humans Survival rate Aged Lung business.industry Stomach Thyroid General Medicine Middle Aged medicine.disease Liver Transplantation Survival Rate medicine.anatomical_structure 030220 oncology & carcinogenesis Hepatocellular carcinoma 030211 gastroenterology & hepatology Female Neoplasm Recurrence Local business |
| Zdroj: | Bioscience trends. 14(1) |
| ISSN: | 1881-7823 |
| Popis: | Posttransplant malignancy has become a significant cause of mortality. Data on the long-term outcomes of patients with pretransplant nonhepatic malignancy (PTM) after living donor liver transplantation (LDLT) are scarce, although the recipients of other organs with PTM have been reported to have a poor survival. Fifteen patients with PTM (4.4%) among the 342 adult recipients were identified in our LDLT programs. The outcomes of the patients with PTM after LDLT were compared to those of patients without PTM in terms of the all-cause mortality and cancer-specific mortality (defined as mortality related to malignancy expect for hepatocellular carcinoma, cholangiocarcinoma, or neuroendocrine tumor). The sites of PTM included the breast in six, stomach in two, and colon, lung, kidney, uterine, thyroid, larynx, and acute myelogenous leukemia in one each. The median interval from the PTM treatment to LDLT was 57 months (range, 2-298). The patients who received the curative treatment for PTM were selected as the recipients. No patients with PTM had recurrence during the follow-up period. The 1-, 5-, and 10-year patient survival rates were 100%, 92.9%, and 92.9% in the PTM group and 86.2%, 76.7%, and 68.5% in the non-PTM group, respectively (p = 0.142). Likewise, there was no significant difference between the two groups in the cancer-specific mortality. In conclusion, the patients with PTM had comparable outcomes with regard to mortality and cancer-specific mortality compared with those without PTM. This study showed that the patients with PTM can obtain an acceptable outcome after LDLT when carefully selected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|